Literature DB >> 11014456

Chronic neuropathic pain: mechanisms and treatment.

N Attal1.   

Abstract

There have been considerable advances in our understanding of the pathophysiology of neuropathic pain. There is still a lack of consensus about the optimal therapeutic strategy of such conditions, however. Drugs are generally selected on the basis of their established efficacy in randomized controlled studies in etiologically based groups of patients. These studies have been important in confirming the efficacy of antidepressants, antiepileptics, local anesthetics and derivatives, capsaicin, opioids, and N-methyl-D-aspartate antagonists in neuropathic pain, specifically painful diabetic neuropathy and postherpetic neuralgia. More specific therapeutic strategies based on precise quantified assessment of the various components of neuropathic pain are now increasingly used and may provide insight regarding the effects of treatments of particular symptoms (e.g., allodynia, hyperalgesia). In some cases, such assessment may also help to analyze the mechanisms involved in pain, thus allowing selection of treatment on a more rational basis. A mechanism-based approach seems promising for clinical research studies, although its application in current management remains challenging.

Entities:  

Mesh:

Year:  2000        PMID: 11014456     DOI: 10.1097/00002508-200009001-00003

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  3 in total

Review 1.  Pharmacotherapy for pain in rheumatologic conditions: the neuropathic component.

Authors:  Keri L Fakata; Arthur G Lipman
Journal:  Curr Pain Headache Rep       Date:  2003-06

Review 2.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

3.  The diagnosis and management of neuropathic pain in daily practice in Belgium: an observational study.

Authors:  Guy Hans; Etienne Masquelier; Patricia De Cock
Journal:  BMC Public Health       Date:  2007-07-24       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.